enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Olanzapine/fluoxetine - Wikipedia

   en.wikipedia.org/wiki/Olanzapine/fluoxetine

   Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. [1] In 2009, it was granted approval for the treatment of treatment-resistant depression.

3. Fluvoxamine - Wikipedia

   en.wikipedia.org/wiki/Fluvoxamine

   It was one of the first SSRI antidepressants to be launched, and is prescribed in many countries to patients with major depression. [96] It was the first SSRI, a non-TCA drug, approved by the U.S. FDA specifically for the treatment of OCD. [97] At the end of 1995, more than ten million patients worldwide had been treated with fluvoxamine.

4. List of antidepressants - Wikipedia

   en.wikipedia.org/wiki/List_of_antidepressants

   Amisulpride (Solian) – approved in low doses as a monotherapy for persistent depression and major depressive disorder [10] Levosulpiride – approved in low doses for major depressive disorder [11] Lumateperone (Caplyta) – approved as a monotherapy for bipolar depression; Lurasidone (Latuda) – approved as a monotherapy for bipolar depression

5. Escitalopram (Lexapro): Everything You Need to Know Before ...

   www.aol.com/escitalopram-lexapro-everything-know...

   The FDA also approves it for the treatment of generalized anxiety disorder (GAD). ... obsessive-compulsive disorder, bipolar disorder, premenstrual dysphoric disorder (PMDD), post-traumatic stress ...

6. FDA approves first fast-acting oral drug for clinical depression

   www.aol.com/fda-approves-first-fast-acting...

   Story at a glance A newly approved treatment for clinical depression is being hailed as a potential game changer for the millions of Americans who suffer from the condition. Auvelity, from Axsome ...

7. FDA approves standalone use of J&J’s ketamine-derived ... - AOL

   www.aol.com/fda-approves-standalone-j-j...

   The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...